Bionet held its performance presentation on the 26th. CEO Michael Kang announced that in the first half of the year, the company successfully expanded into 11 different sectors—including healthcare, cosmetics manufacturing, traditional Chinese medicine, pharmaceuticals, and aromatherapy—through its new business model focused on exosome global R&D and contract manufacturing (Exosome Foundry). The number of transaction clients increased eightfold within six months, driving first-half revenue to reach a record high for the period. Revenue from exosome-related business grew by 182% compared to the same period last year. In the second half, Bionet plans to launch next-generation exosome products and collaborate with nearly 500 long-term partner OB-GYN clinics to drive new growth in regenerative medicine.
Additionally, Kang revealed that Bionet’s subsidiary, Bionet Therapeutics, after qualifying under the "Biotechnology and Pharmaceutical Industry Development Act," is now actively pursuing the high standards set by the Ministry of Economic Affairs' review of technology enterprises, particularly focusing on "successful product development with market potential." The company plans to apply for listing on the Emerging Market Board in the fourth quarter. Bionet Therapeutics is currently in Phase II clinical trials for its new mesenchymal stem cell drug BU-01. The company's ExoTear, a new exosome drug for dry eye syndrome, has received guidance from the Center for Drug Evaluation (CDE) as a key project. The drug's differentiated features include five patents covering exosome preparation techniques and immunomodulatory properties, which help repair corneal function and offer anti-inflammatory benefits.
Bionet has long been dedicated to neonatal stem cell transplantation for treating blood disorders, metabolic abnormalities, and immune deficiencies. Recognizing the potential of exosomes, Bionet has expanded into multiple specialties—including plastic surgery, dermatology, orthopedics, ophthalmology, obstetrics and gynecology, and reproductive medicine—conducting over 10 clinical research projects combining exosomes with cell therapy for regenerative medicine, thus advancing its strategy for regenerative medicine upgrades.
Kang emphasized that Bionet will collaborate with nearly 500 OB-GYN clinics across Taiwan, leveraging amniotic fluid exosomes and umbilical cord blood exosomes to assist in clinical research in reproductive medicine, including ovarian insufficiency, thin endometrium, vaginal tightening, stretch marks, postpartum hair loss, and skin inflammation. With the launch of next-generation exosome products, Bionet aims to provide new value-added services and seize emerging opportunities in regenerative medicine.
Moreover, as Taiwan approaches an ultra-aging society next year, the demand for anti-aging treatments and unmet medical needs will drive the expansion of the regenerative medicine market. To date, Bionet has received approval from the Ministry of Health and Welfare for 56 projects under the "Special Regulations" program, with the highest number of approved adipose-derived stem cell projects in Taiwan. As of the end of June, Bionet also had the highest number of enrolled cases for adipose-derived stem cell therapy, accounting for 80% of all cases in Taiwan. Among these, the demand for treating degenerative arthritis is the strongest, with excellent results—pain levels decreased by 60% and knee joint function improved by 70% one year after treatment.
Kang is optimistic about the global regenerative medicine market. According to MarketWatch research, the market is projected to reach $531.7 billion by 2033, with a compound annual growth rate (CAGR) of 32.4% from 2024 to 2033.
Resource (mandarin): 訊聯攜500家婦產科搶攻外泌體 子公司訊聯細胞智藥Q4登興櫃
